business

B2i Digital Established as Marketing Partner for the 3rd Annual ROTH Healthcare Opportunities Conference

NEW YORK, NY, UNITED STATES,19th Sept 2024- B2i Digital, Inc. has been selected as a marketing partner for the 3rd Annual ROTH Healthcare Opportunities Conference, a key networking event connecting executives from 30+ public companies with institutional investors. The conference is scheduled for October 9, 2024, at the Metropolitan Club in New York, NY.

The ROTH Healthcare Opportunities Conference will feature one-on-one and small group meetings between company management and investors, focusing on various healthcare subsectors, including Biotechnology, Brain Disorders, Medical Technologies, Oncology Therapeutics, and Pharmaceuticals. The event includes themed industry panels, breakfast and lunch panels featuring industry experts, and a cocktail reception for networking.

As the marketing partner, B2i Digital will create comprehensive digital profiles of the participating companies on its platform, b2idigital.com. These profiles will offer investors insights into each company’s offerings, strategies, and potential prior to the conference.

“The healthcare sector remains at the forefront of innovation and investment potential,” said David Shapiro, CEO of B2i Digital. “Our partnership with the ROTH Healthcare Opportunities Conference allows us to highlight these pioneering and innovative companies, providing investors with valuable insights into the future of healthcare.”

B2i Digital’s collaboration with the ROTH Healthcare Opportunities Conference underscores its commitment to leveraging both advanced digital marketing technologies and in-person events to connect growth companies with sophisticated investors.

To attend the conference, participants can submit a registration request at https://b2idigital.com/3rd-annual-roth-healthcare-opportunities-conference

Attending Company List As of 9/18/24:

Allurion Technologies, Inc. (ALUR)
Beyond Air, Inc. (XAIR)
Biofrontera Inc. (BFRI)
BioRestorative Therapies, Inc. (BRTX)
Cardiol Therapeutics Inc. (CRDL)
Cellectar Biosciences, Inc. (CLRB)
CervoMed Inc. (CRVO)
Chemomab Therapeutics Ltd. (CMMB)
Cingulate Inc. (CING)
Cognition Therapeutics, Inc. (CGTX)
Entero Therapeutics Inc. (ENTO)
Fortress Biotech, Inc. (FBIO)
Gain Therapeutics, Inc. (GANX)
GeoVax Labs, Inc. (GOVX)
GT Biopharma, Inc. (GTBP)
iRadimed Corp. (IRMD)
Journey Medical Corp. (DERM)
Longeveron Inc (LGVN)
Moleculin Biotech, Inc. (MBRX)
Nuvectis Pharma, Inc. (NVCT)
Nuwellis, Inc. (NUWE)
Oncolytics Biotech Inc. (ONCY)
Orthofix Medical Inc. (OFIX)
Ovid Therapeutics Inc. (OVID)
Replimune Group, Inc. (REPL)
Revelation Biosciences, Inc. (REVB)
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Sensus Healthcare, Inc. (SRTS)
Stereotaxis, Inc. (STXS)
TFF Pharmaceuticals, Inc. (TFFP)
TriSalus Life Sciences, Inc. (TLSI)
Zevra Therapeutics, Inc. (ZVRA)

Leave a Reply

Your email address will not be published. Required fields are marked *